Immunotherapy for head and neck cancer

At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover, Germany, highlights recent advances in the treatment of patients with head and neck cancer, including the increasing interest in immunotherapy with the programmed death (PD-1) inhibitors, pembrolizumab and nivolumab.